- Home
- FMST vs NRSN Comparison
FMST vs NRSN Comparison
Compare FMST & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMST | NRSN |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 26.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FMST | NRSN |
|---|---|---|
| Price | $2.50 | $0.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 315.7K | ★ 400.5K |
| Earning Date | 11-13-2025 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.81 |
| 52 Week High | $5.74 | $2.60 |
Technical Indicators
Market Signals| Indicator | FMST | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 32.97 |
| Support Level | $2.48 | $0.82 |
| Resistance Level | $3.49 | $0.93 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 2.97 | 7.74 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.